Abstract: Methods and uses for treating an adrenal gland tumor in a subject suffering therefrom are disclosed, to reduce the size or tumor load of, prevent the growth of, or slow the growth of, or reduce or alter secretions from, or induce degeneration or apoptosis in, the adrenal gland tumor. The novel treatments include use of, or administration of, an effective amount of the glucocorticoid receptor modulator (GRM) compound having a heteroaryl-ketone fused azadecalin structure to a patient suffering from an adrenal gland tumor. The adrenal gland tumor may be a benign adrenal gland tumor. The GRM may be relacorilant, which is ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone). The GRM may be orally administered. The GRM may be administered with food. The treatments may be used in the absence of surgery, or prior to, or during, or after surgery for the adrenal gland tumor.

Abstract: The invention relates to a method of inhibiting viral replication by topically administering imiquimod, {1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine} or by administering imiquimod cocrystals (made with ferulic, acetic, tartaric, citric or coumaric acid). Another aspect of the invention is a method of preventing or reducing the severity of an infection by topically administering by imiquimod, or one of these cocrystals. Another aspect is administering imiquimod or one of these cocrystals in a nasal spray.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: A composition and method for improving mental function and physical performance with aging is disclosed. The composition comprises Rhus succedanea stem extract standardized for Fisetin, Piper longum root extract standardized for Piperlongumine, and Sophora japonica L. flower extract standardized for Quercetin. The composition may optionally include Sophora japonica L. flower extract standardized for Luteolin, Curcuma longa root standardized for curcuminoids, Olive Leaf extract standardized for olive polyphenols, milk thistle seed extract standardized for silymarin, soybean seed extract standardized for soy isoflavones, and Senactive® senolytic or combinations thereof. The composition is formulated for oral administration and may be taken intermittently for a couple to a few days at a time, followed by a week to several weeks without supplementation, with this dosing regimen repeated.

Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Abstract: Disclosed herein are pyridyl compounds. Also described are specific conjugated nicorandil compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the pyridyl compounds are disclosed for the treatment of diseases or conditions related to kidney or kidney functions.

Abstract: The present disclosure relates to dosing regimens of an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: This invention relates to compounds having the generic structure of formula I: X-L-Y—Z I which are useful in the treatment of a bacterial infection caused by Mycobacterium abscessus, where: X is selected from an unsubstituted or substituted phenyl, pyridyl, quinazolinyl, or naphtyl; Y is an unsubstituted or substituted heteroaryl ring system selected from benzimidazolyl, benzothiazolyl, benzofuranyl, quinazolinyl, and naphthyl; Z is selected from H, phenyl and pyridyl, where the phenyl and pyridyl groups are unsubstituted or substituted; L is selected from —CH2NHCOCH2CH2- or —CH2-phenyl-CH2, —CH2-, —NH-pyrrolyl, imidazolyl, and thiazolyl or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, including carnitine acylcarnitine carrier (CAC) inhibitor and an anticancer agent. The compositions comprising the carnitine acylcarnitine carrier inhibitor and the anticancer agent of the present invention not only significantly reduced the growth of various cancer cells compared to the use of the carnitine acylcarnitine carrier inhibitor or the anticancer agent alone, but also confirmed the anti-cancer synergistic effect of co-administration of the carnitine acylcarnitine carrier inhibitor and the anticancer agent in a xenograft tumor animal model. Thus, the composition of the present invention is useful as effective combination anticancer agent.

Abstract: Methods of treating an individual experiencing or at risk of experiencing an undesired consequence of opioid use, and of treating an individual who is experiencing or at risk of experiencing a craving for an opioid, as well as the use of the NK-1 receptor antagonist, tradipitant, in the treatment of such an individual are disclosed herein.

Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme.

Abstract: The present application is directed to inhibitors of iRhom2/ADAM17 activity that are useful in the treatment of various diseases.

Abstract: Haloperidol, or a pharmaceutically acceptable salt, ester or solvate thereof, as well as pharmaceutical compositions comprising the same, for use in methods for preventing and/or treating spinal muscular atrophy, are described.

Abstract: The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.

Abstract: Methods of further reducing cardiovascular risk in subjects with coronary artery disease on moderate intensity statins. For example, methods may prevent an adverse cardiovascular event in a subject in need thereof, on a dosage of 1 mg/day pitavastatin or a pharmaceutically acceptable salt thereof, when the subject has an LDL-C concentration less than 120 mg/dL, by increasing the dosage to 4 mg/day for a therapeutically effective period of time.

Abstract: Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and/or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.

Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel, a P-gp inhibitor, and a checkpoint inhibitor. The pharmaceutical combinations are suitable for the treatment of a cancer (e.g., lung cancer) in a subject.

Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Abstract: The present embodiments are directed to methods of using a crystalline form (such as form A, B, or C, or a methylparaben cocrystal form) or an amorphous form of Bitopertin, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.

Abstract: The present invention relates to granules preferably prepared by subjecting a mixture containing posaconazole, an enteric polymer and optionally a non-enteric polymer to hot-melt extrusion, whereby the granules have a specific particle-size distribution and contain the drug in molecularly dispersed form, and a gastro-resistant, optionally film-coated tablet prepared from the granules.

Abstract: The claimed invention is directed towards a composition for promoting NR4A2 (nurr1) activity, CREB1 activity, NGF-independent TRKA activation, terpenoid backbone biosynthesis, or any combination thereof, in a cell, tissue, organ, subject, patient and/or organism, wherein the composition comprises an aminopyridine, its derivatives, its metabolites, its analogs, and/or its isomers. The invention also provides a method for promoting NR4A2 (nurr1) activity, CREB1 activity, NGF-independent TRKA activation, terpenoid backbone biosynthesis, or any combination thereof, in a cell, tissue, organ, subject, patient and/or organism, wherein said method comprises treatment of said cell, tissue, organ, organism, individual, and/or patient with the composition.

Abstract: The present invention relates to stable liquid composition suitable for parenteral administration in the form of a solution comprising: (a) netupitant at a concentration of about 0.5 mg/mL to about 20 mg/ml; (b) at least one pharmaceutically acceptable stabilizer at a concentration of 1 mg/mL to 22 mg/mL selected from the group consisting of tromethamine, phosphoric acid, aspartic acid, tartaric acid, citric acid, maleic acid, ascorbic acid and mixtures thereof; and (c) at least one pharmaceutically acceptable vehicle, wherein the composition is in the form of a solution and has a pH of 2 to 6. The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.

Abstract: Disclosed herein are pharmaceutical compositions and methods for the treatment and prophylaxis of bacterial infections of the skin, including, topical ulcers caused by Mycobacterium ulcerans in Buruli ulcers, and/or other topical infections and types of inflammation. In particular, the compositions comprise clofazimine, derivatives thereof, polymorphs thereof, and/or analogs thereof in a solution, suspension, creams, oils, emulsions, and ointments for topical application. Methods for making the compositions are also disclosed.

Abstract: The present disclosure is directed to methods for treating vitiligo using the selective JAK1 inhibitor upadacitinib.

Abstract: The disclosure includes compounds of Formula (I) wherein Warhead, Q0, Q1, Q2, Q3, Q4, Z, W, i, j, k, m, n, L1, L2, L3, L4, L5, L6, R0, R1, R2, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

Abstract: Disclosed are methods of treating psoriatic arthritis in a subject comprising administering to the subject a TYK2 inhibitor (e.g., deucravacitinib), wherein the methods depend on whether the subject exhibits certain levels of specific proteins in the blood (e.g., plasma or serum) prior to or early during administration of the TYK2 inhibitor. Also disclosed are methods for selecting subjects suffering from psoriatic arthritis for treatment with a TYK2 inhibitor, wherein subjects are selected based on the level of one or more proteins in the blood prior to treatment with a TYK2 inhibitor.

Abstract: The present disclosure provides compositions and methods for the treatment of pathogen-induced and/or chemical-induced lung injury, for regenerating lung epithelial cells following lung injury, for treating cancer, and for sensitizing a subject suffering from cancer to a chemotherapeutic agent.

Abstract: The present disclosure relates to a method of treating an acute inflammatory condition in a subject comprising administering to the subject a therapeutically effective amount of a heteroaryl or heterocyclic compound.

Abstract: Methods of preventing or treating an immune-mediated hair-loss disorder such as alopecia areata in a mammalian subject include administering an inhibitor of TYK2 to the mammalian subject. TYK2 inhibitors useful in such methods include a compound having the structure of Formula (I) as set forth herein, and a compound having the structure of Formula (II) as set forth herein.

Abstract: Described herein are methods and compositions for treating tumors harboring gene fusions. In some embodiments, the present disclosure provides a method of treating tumors harboring gene fusions comprising administering to a subject in need thereof a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof. In some embodiments, the Raf kinase inhibitor or a pharmaceutically acceptable salt thereof is (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl) thiazole-5-carboxamide. In some embodiments, the gene fusion is a CRAF gene fusion, a BRAF gene fusion, or both.

Abstract: The present disclosure provides a method of using mocetinostat in combination with vinorelbine to treating a patient with rhabdomyosarcoma (RMS). The patient can be a child, an adolescent, or an adult having a locally advanced RMS, an unresectable RMS, a metastatic RMS, or a recurrent RMS.

Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

Abstract: A method to inhibit adverse pregnancy outcomes in a pregnant mammal via administering to the pregnant mammal who is concurrently taking a selective serotonin reuptake inhibitor (SSRI) a therapeutically effective amount of a serotonin receptor antagonist.

Abstract: The present invention relates to a composition for the prevention or treatment of neurodegenerative or motor neuron diseases comprising halofuginone as an active ingredient. Specifically, in Amyotrophic Lateral Sclerosis (ALS) cell and animal models, halofuginone inhibits fibrosis induced by elevated TGF-?, enhances skeletal muscle formation, improves joint contracture, and exhibits dual effects of suppressing inflammatory responses and neuronal cell death in the central nervous system, and then, halofuginone leads to the delay in the progression of ALS symptoms, improvement in performance capabilities, and extension of survival duration. Consequently, halofuginone can be usefully utilized as an active ingredient in a composition for the prevention or treatment of neurodegenerative or motor neuron diseases including ALS.

Abstract: The present application provides methods of treating a disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a JAK1 selective inhibitor, or a pharmaceutically acceptable salt thereof.

Abstract: Described herein are methods for preventing or treating KRAS mutant pancreatic cancer in a subject in need thereof comprising administering to the subject an effective amount of (i) an effective amount of a PRC2 inhibitor, (ii) an effective amount of a MEK inhibitor, (ii) and an effective amount of a CDK4/6 inhibitor, as well as compositions and kits for use in said methods.

Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.

Abstract: The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

Abstract: Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an inhibitor of the super elongation complex (SEC). In various embodiments, the cancer is a blood cancer. Wherein the blood cancer is selected from the group consisting of leukemia, lymphoma, myeloma, and myeloproliferative neoplasms (MPNs).

Abstract: The present invention relates to dioxazines, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.

Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.

Abstract: The present invention relates to therapeutic uses of active agents such as for treating, inhibiting, and/or preventing damage associated with aminoglycoside toxicity. The data establishes that piperlongumine can protect hair cells from aminoglycoside damage within a wide range of concentrations. The range is 0.1 pM to 25 uM. Furthermore, piperlongumine protects renal function, it has a good therapeutic index (TI>200,000), no interference with AG's anti-bacterial activity, and no drug-drug interaction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed herein are methods, compositions, and kits for treating a subject in need of a treatment for a cancer. The method comprises administering to the subject a CDK8/19 inhibitor and a mTOR inhibitor.

Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.

Abstract: A series of tricyclic compounds and the use thereof. Specifically disclosed are a compound as represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of certain oncogenic proteins.

Abstract: The present invention relates the compound hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester (Compound (I)) effective for treating normal tension glaucoma, neovascular glaucoma and ocular diseases associated with retinopathy.